Evidence map›Paper›PMID 38497670›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

IL-10 Differentially Promotes Mast Cell Responsiveness to IL-33, Resulting in Enhancement of Type 2 Inflammation and Suppression of Neutrophilia.

Saurav Ranjitkar, Dylan Krajewski, Chelsea Garcia, Caitlin Tedeschi, Stephanie H Polukort, Jeffrey Rovatti, Mohamed Mire, Christopher N Blesso, Evan Jellison, Sallie S Schneider and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Saurav RanjitkarDepartment of Nutritional Sciences, University of Connecticut, Storrs, CT.
Dylan KrajewskiDepartment of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.
Chelsea GarciaDepartment of Nutritional Sciences, University of Connecticut, Storrs, CT.ORCID 0000-0002-7681-695X
Caitlin TedeschiDepartment of Nutritional Sciences, University of Connecticut, Storrs, CT.
Stephanie H PolukortDepartment of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.ORCID 0009-0004-3323-2374
Jeffrey RovattiDepartment of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.
Mohamed MireDepartment of Pharmaceutical and Administrative Sciences, Western New England University, Springfield, MA.ORCID 0000-0003-2468-5289
Christopher N BlessoDepartment of Nutritional Sciences, University of Connecticut, Storrs, CT.
Evan JellisonDepartment of Immunology, University of Connecticut, Farmington, CT.ORCID 0009-0004-2674-1605
Sallie S SchneiderPioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield, MA.ORCID 0000-0003-0093-4308
John J RyanDepartment of Biology, Virginia Commonwealth University, Richmond, VA.
Clinton B MathiasDepartment of Nutritional Sciences, University of Connecticut, Storrs, CT.ORCID 0000-0002-0223-4842
University of Connecticut · USWestern New England University · USBaystate Medical Center · USVirginia Commonwealth University · US

Funding

GGT Targeting Suppresses Mast Cell Activation by IgE and IL-33R01AI138495 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI RYAN, JOHN J · 2018 to 2022
$2.2M
P2X3 is a Female-Dominant Amplifier of Mast Cell FunctionR01AI164710 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI RYAN, JOHN J · 2021 to 2025
$1.8M
Differential regulation of mast cell-mediated allergic responses by IL-10R01AI167884 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI Clinton B Mathias · 2023 to 2026
$1.8M
Inhibitory effects of curcumin on Th2 sensitization and mast cell function in a mR15AI107668 · NIAID · WESTERN NEW ENGLAND UNIVERSITY · PI MATHIAS, CLINTON B · 2014 to 2014
$348k
NIAID NIH HHS R01 AI138495NIAID NIH HHS R01 AI164710NIAID NIH HHS R01 AI167884NIAID NIH HHS R15 AI107668
6 · The paper itself

Abstract

Mast cells (MCs) play critical roles in the establishment of allergic diseases. We recently demonstrated an unexpected, proinflammatory role for IL-10 in regulating MC responses. IL-10 enhanced MC activation and promoted IgE-dependent responses during food allergy. However, whether these effects extend to IgE-independent stimuli is not clear. In this article, we demonstrate that IL-10 plays a critical role in driving IL-33-mediated MC responses. IL-10 stimulation enhanced MC expansion and degranulation, ST2 expression, IL-13 production, and phospho-relA upregulation in IL-33-treated cells while suppressing TNF-α. These effects were partly dependent on endogenous IL-10 and further amplified in MCs coactivated with both IL-33 and IgE/Ag. IL-10's divergent effects also extended in vivo. In a MC-dependent model of IL-33-induced neutrophilia, IL-10 treatment enhanced MC responsiveness, leading to suppression of neutrophils and decreased TNF-α. In contrast, during IL-33-induced type 2 inflammation, IL-10 priming exacerbated MC activity, resulting in MC recruitment to various tissues, enhanced ST2 expression, induction of hypothermia, recruitment of eosinophils, and increased MCPT-1 and IL-13 levels. Our data elucidate an important role for IL-10 as an augmenter of IL-33-mediated MC responses, with implications during both allergic diseases and other MC-dependent disorders. IL-10 induction is routinely used as a prognostic marker of disease improvement. Our data suggest instead that IL-10 can enhance ST2 responsiveness in IL-33-activated MCs, with the potential to both aggravate or suppress disease severity depending on the inflammatory context.

Indexed as

Food HypersensitivityMast CellsCell DegranulationHumansImmunoglobulin EInflammationInterleukin-10Interleukin-13Interleukin-1 Receptor-Like 1 ProteinInterleukin-33Tumor Necrosis Factor-alphaImmunoglobulin EInterleukin-10Interleukin-13Interleukin-1 Receptor-Like 1 ProteinInterleukin-33Tumor Necrosis Factor-alpha

Identifiers

PMID38497670
PMCPMC11018500
OpenAlexW4392912111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.